Development of AAV vectors for CF therapy
用于 CF 治疗的 AAV 载体的开发
基本信息
- 批准号:10544549
- 负责人:
- 金额:$ 38.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-12-15 至 2024-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAirway DiseaseAnimal ModelBindingBlindnessBloodBlood Coagulation DisordersBlood VesselsCRISPR/Cas technologyCapsidClinical TrialsComplicationCystic FibrosisCystic Fibrosis Transmembrane Conductance RegulatorDNADependovirusDevelopmentDirected Molecular EvolutionDiseaseEpithelial CellsFailureGene DeliveryGenesGenetic DiseasesGenetic EngineeringGenomeHemorrhageHigh PrevalenceHumanIn VitroIncubatedIntravenous ImmunoglobulinsLibrariesLongitudinal StudiesLungLung diseasesMeasurableMediatingMorbidity - disease rateMusMutationOrganPatientsPeptidesPeripheralPersonsPhage DisplayPhenotypePropertyProteinsRegulator GenesSerotypingTechnologyTestingTissuesTransduction GeneVariantVascular PermeabilitiesViral GenomeViral PackagingVirionadeno-associated viral vectorairway epitheliumapical membraneautosomebasolateral membranecellular transductioncystic fibrosis airway epitheliacystic fibrosis mousecystic fibrosis patientsdelivery vehicleds-DNAearly phase clinical trialgene therapyimprovedmortalitymutantneutralizing antibodynovelnovel strategiespulmonary functionrecessive genetic traitsmall moleculesuccesstransduction efficiencyvectorvector induced
项目摘要
Abstract
Cystic fibrosis (CF) is caused by mutations of the CF transmembrane conductance regulator (CFTR) gene.
Airway disease is the leading cause of morbidity and mortality. Gene therapy offers a potential cure for CF.
Among gene delivery vehicles, adeno-associated virus (AAV) vectors have demonstrated success in clinical
trials. AAV vectors have also been tested in CF patients via airway delivery for gene addition but without
measurable success perhaps due to physical airway barriers and inefficient transduction. Studies have shown
that higher AAV transduction of airway epithelial cells occur via the basolateral membrane in vitro and our
preliminary study demonstrated that systemic administration of AAV vectors induced much more efficient lung
transduction than airway delivery in mice. These findings strongly suggest that AAV can transduce airway
epithelial cells via systemic administration. The efficiency of AAV transduction in airway epithelial cells after
systemic delivery of AAV vectors is usually restricted by the blood vascular barrier and a high prevalence of
AAV neutralizing antibodies (Nabs). In this proposal, based on our previous studies, we will explore different
strategies to develop novel AAV vectors using directed evolution and AAV virion specific binding peptides via
phage display technology to increase AAV vector vascular permeability for enhanced transduction in airway
epithelial cells and to evade Nabs after systemic administration. Finally, the novel approaches developed in
this proposal will be used to deliver optimized CRISPR/Cas9 specific for CFTR del508 to CF mice and study
the long-term phenotypic correction. The results generated from these studies will allow us to develop an
effective approach to treat CF patients using AAV vector mediated gene delivery.
.
摘要
囊性纤维化(CF)是由CF跨膜传导调节因子(CFTR)基因突变引起的。
气道疾病是发病率和死亡率的主要原因。基因治疗为CF提供了一种潜在的治疗方法。
在基因递送载体中,腺相关病毒(AAV)载体已经在临床上显示出成功。
审判AAV载体也已经在CF患者中通过气道递送进行了基因添加的测试,但没有
可测量的成功可能是由于物理气道屏障和低效的转导。研究表明
在体外,气道上皮细胞通过基底外侧膜进行更高的AAV转导,
初步研究表明,AAV载体的全身给药诱导了更有效的肺
在小鼠中,转导比气道递送更有效。这些发现强烈提示AAV可以阻断气道
上皮细胞通过全身给药。AAV转导在气道上皮细胞中的效率
AAV载体的全身递送通常受到血管屏障的限制,并且AAV载体的高患病率是一个很大的障碍。
AAV中和抗体(Nabs)。在这个建议中,基于我们以前的研究,我们将探索不同的
利用定向进化和AAV病毒体特异性结合肽开发新型AAV载体的策略,
噬菌体展示技术增加腺相关病毒载体血管渗透性以增强气道转导
上皮细胞,并在全身给药后逃避Nabs。最后,新的方法,
该提案将用于向CF小鼠递送对CFTR del 508特异性的优化CRISPR/Cas9,并研究
长期的表型校正。从这些研究中产生的结果将使我们能够制定一个
使用AAV载体介导的基因递送治疗CF患者的有效方法。
.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chengwen Li其他文献
Chengwen Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chengwen Li', 18)}}的其他基金
Novel strategy to block Nabs for AAV gene delivery
阻断 Nabs 进行 AAV 基因传递的新策略
- 批准号:
10570881 - 财政年份:2022
- 资助金额:
$ 38.88万 - 项目类别:
Novel strategy to block Nabs for AAV gene delivery
阻断 Nabs 进行 AAV 基因传递的新策略
- 批准号:
10416627 - 财政年份:2022
- 资助金额:
$ 38.88万 - 项目类别:
Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion
具有人肝细胞趋向性和中和抗体逃避性的AAV载体的合理设计
- 批准号:
10546241 - 财政年份:2022
- 资助金额:
$ 38.88万 - 项目类别:
Development of AAV vectors for CF therapy
用于 CF 治疗的 AAV 载体的开发
- 批准号:
10117463 - 财政年份:2020
- 资助金额:
$ 38.88万 - 项目类别:
Develop humanized AAV vectors for liver targeting and neutralizing antibody evasion
开发用于肝脏靶向和中和抗体逃避的人源化 AAV 载体
- 批准号:
10079155 - 财政年份:2020
- 资助金额:
$ 38.88万 - 项目类别:
Development of AAV vectors for CF therapy
用于 CF 治疗的 AAV 载体的开发
- 批准号:
10319017 - 财政年份:2020
- 资助金额:
$ 38.88万 - 项目类别:
Novel strategy to block AAV neutralizing anitbody activity
阻止 AAV 中和抗体活性的新策略
- 批准号:
10080225 - 财政年份:2020
- 资助金额:
$ 38.88万 - 项目类别:
Optimization of AAV vector to deliver FVa for hemophilia with inhibitors
优化 AAV 载体以通过抑制剂递送血友病 FVa
- 批准号:
10372097 - 财政年份:2019
- 资助金额:
$ 38.88万 - 项目类别:
Enhance AAV Liver Transduction with Capsid Immune Evasion
通过衣壳免疫逃避增强 AAV 肝脏转导
- 批准号:
9098885 - 财政年份:2016
- 资助金额:
$ 38.88万 - 项目类别:
Enhance AAV Liver Transduction with Capsid Immune Evasion
通过衣壳免疫逃避增强 AAV 肝脏转导
- 批准号:
9893176 - 财政年份:2016
- 资助金额:
$ 38.88万 - 项目类别:
相似海外基金
EXposomic Profiling in Airway disease to uNravel Determinants of disease in Asthma (EXPAND-Asthma) Center
气道疾病暴露组分析以解开哮喘疾病的决定因素 (EXPAND-Asthma) 中心
- 批准号:
10744673 - 财政年份:2023
- 资助金额:
$ 38.88万 - 项目类别:
Bacteriophage as a predictive biomarker in chronic Pseudomonas airway disease
噬菌体作为慢性假单胞菌气道疾病的预测生物标志物
- 批准号:
10723956 - 财政年份:2023
- 资助金额:
$ 38.88万 - 项目类别:
Defining a gene expression signature of airway disease, COPD exacerbations, and response to treatment
定义气道疾病、COPD 恶化和治疗反应的基因表达特征
- 批准号:
10733573 - 财政年份:2023
- 资助金额:
$ 38.88万 - 项目类别:
Impact of Maternal Arsenic Exposure on Offspring's Epigenetic Reprogramming of Allergic Airway Disease
母亲砷暴露对后代过敏性气道疾病表观遗传重编程的影响
- 批准号:
10733607 - 财政年份:2023
- 资助金额:
$ 38.88万 - 项目类别:
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
- 批准号:
10716654 - 财政年份:2023
- 资助金额:
$ 38.88万 - 项目类别:
Immune Mediators of IL-22 Signaling Alter Allergic Airway Disease
IL-22 信号的免疫介质改变过敏性气道疾病
- 批准号:
10853347 - 财政年份:2023
- 资助金额:
$ 38.88万 - 项目类别:
Microbial adaptation of Pseudomonas lipid A structure in CF airway disease progress
假单胞菌脂质 A 结构在 CF 气道疾病进展中的微生物适应
- 批准号:
10722599 - 财政年份:2023
- 资助金额:
$ 38.88万 - 项目类别:
The role of anaerobic microbiota in cystic fibrosis airway disease trajectory
厌氧微生物群在囊性纤维化气道疾病轨迹中的作用
- 批准号:
10985906 - 财政年份:2023
- 资助金额:
$ 38.88万 - 项目类别:
Mentoring patient-oriented researchers in inflammatory airway disease
指导炎症性气道疾病领域以患者为中心的研究人员
- 批准号:
10657746 - 财政年份:2022
- 资助金额:
$ 38.88万 - 项目类别: